StockData
Merck & Co., Inc. logo

Merck & Co., Inc.

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$149.52+3.19 (+2.18%)

Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%

Merck Emend (aprepitant/fosaprepitant by Year

Emend (aprepitant/fosaprepitant — CINV supportive care, legacy) — International sales ($M) ($M)

Merck Emend (aprepitant/fosaprepitant: $127M in FY2020, down 38.0% from a year earlier. No newer figure appears in the documents we track.

Latest, FY2020
127
Period ended Dec 31, 2020
Change on a year earlier
-38.0%
205 in FY2019
History
5 years
Since FY2016
Sources
3
Documents cited below

Where the FY2020 figure comes from

Source: Form 10-K (filed 2021-02-25) ↗

Reported in Form 10-Q / 10-K Segment & Product Sales Footnote & Form 8-K Table 3 / 3a / 3b.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedEmend (aprepitant/fosaprepitant — CINV supportive care, legacy) — International sales ($M) ($M)Year on yearSource
FY2020Dec 31, 2020127-38.0%Form 10-K (filed 2021-02-25) ↗
FY2019Dec 31, 2019205-2.4%Form 10-K (filed 2021-02-25) ↗
FY2018Dec 31, 2018210-1.4%Form 10-K (filed 2021-02-25) ↗
FY2017Dec 31, 2017213+10.4%Form 10-K (filed 2020-02-26) ↗
FY2016Dec 31, 2016193–Form 10-K (filed 2019-02-27) ↗

Cite this data

StockData. (2026). Merck Emend (aprepitant/fosaprepitant ($M), annual FY2016–FY2020 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-emend-intl

See every metric in the Merck KPI table. Data updated Oct 26, 2026.